Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioAtla, Inc.BCAB · Entity 879 | Director | June 18, 2025 | June 18, 2025 |
| CELGENE CORP /DE/CELG · Entity 15781 | See Remarks | February 17, 2018 | February 20, 2018 |
| F-star Therapeutics, Inc.SBPH · Entity 115726 | Director | June 24, 2020 | June 25, 2020 |
| TITAN PHARMACEUTICALS INCTTNP · Entity 74432 | Director | September 15, 2017 | September 19, 2017 |
| Viatris IncVTRS · Entity 3277 | Director · Chief Executive Officer | March 06, 2026 | March 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioAtla, Inc.
Report date June 18, 2025 · Filed June 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 321,550 |
Reported balance
After 2025-06-18 transaction · row 1
1 source rowRow 1 · 2025-06-18 · Grant · Acquired 23,500 · Balance 321,550 F1: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026, or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026, or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date.
CELGENE CORP /DE/
Report date February 17, 2018 · Filed February 20, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,419 |
Ending reported balance
After 2018-02-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-02-17 · Exercise / conversion · Acquired 7,283 · Balance 51,748 F1: The performance stock units granted to the reporting person on February 13, 2018 vested and settled for shares of the Company's common stock. Row 2 · 2018-02-17 · Tax withholding · Disposed 2,329 · Balance 49,419 |
| Performance Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-02-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-17 · Exercise / conversion · Disposed 7,283 · Balance 0 F2: Each performance stock unit represents a contingent right to receive one share of the Company's common stock. F3: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F1: The performance stock units granted to the reporting person on February 13, 2018 vested and settled for shares of the Company's common stock. |
| Common StockSEC Table I · non-derivative | Indirect401(k) Plan | 2,788 |
Reported balance
Holding disclosure · report date 2018-02-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,788 |
Filing footnotes · ownership attribution and instrument terms
F1: The performance stock units granted to the reporting person on February 13, 2018 vested and settled for shares of the Company's common stock.
F2: Each performance stock unit represents a contingent right to receive one share of the Company's common stock.
F3: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan.
F-star Therapeutics, Inc.
Report date June 24, 2020 · Filed June 25, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2030-06-23 | Direct | 7,500 |
Reported balance
After 2020-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-24 · Grant · Acquired 7,500 · Balance 7,500 F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 24, 2020, the date of the Issuer's 2020 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 24, 2020, the date of the Issuer's 2020 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.
TITAN PHARMACEUTICALS INC
Report date September 15, 2017 · Filed September 19, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2027-09-15 | Direct | 10,000 |
Reported balance
After 2017-09-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-09-15 · Grant · Acquired 10,000 · Balance 10,000 F1: The option vests in 12 equal monthly installments commencing as of September 1, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in 12 equal monthly installments commencing as of September 1, 2017.
Viatris Inc
Report date March 06, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,329,326 |
Ending reported balance
After 2026-03-06 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-03-06 · Exercise / conversion · Acquired 124,519 · Balance 1,374,576 Row 2 · 2026-03-06 · Tax withholding · Disposed 48,999 · Balance 1,325,577 F1: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on March 6, 2025. Row 3 · 2026-03-06 · Exercise / conversion · Acquired 6,182 · Balance 1,331,759 F2: Fractional shares have been rounded up in connection with the settlement described in footnote 6 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan. Row 4 · 2026-03-06 · Tax withholding · Disposed 2,433 · Balance 1,329,326 F3: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 6, 2025. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 249,036 |
Reported balance
After 2026-03-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-06 · Exercise / conversion · Disposed 124,519 · Balance 249,036 F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). 124,519 of the RSUs granted on March 6, 2025 vested on March 6, 2026 and 124,518 will vest on each of March 6, 2027 and March 6, 2028. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 256,074 |
Reported balance
After 2026-03-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-03-06 · Grant · Acquired 256,074 · Balance 256,074 F7: Each RSU represents the right to receive one share of common stock of Viatris. 85,358 of the RSUs granted on March 6, 2026 will vest on each of March 6, 2027, March 6, 2028, and March 6, 2029. |
| Dividend Equivalent UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 12,362 |
Reported balance
After 2026-03-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-06 · Exercise / conversion · Disposed 6,181.4237 · Balance 12,362 F5: Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. F6: Represents DEUs that accrued with respect to the RSUs previously granted on March 6, 2025 and vest on the same schedule as the underlying RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on March 6, 2025.
F2: Fractional shares have been rounded up in connection with the settlement described in footnote 6 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan.
F3: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 6, 2025.
F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). 124,519 of the RSUs granted on March 6, 2025 vested on March 6, 2026 and 124,518 will vest on each of March 6, 2027 and March 6, 2028.
F5: Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11.
F6: Represents DEUs that accrued with respect to the RSUs previously granted on March 6, 2025 and vest on the same schedule as the underlying RSUs.
F7: Each RSU represents the right to receive one share of common stock of Viatris. 85,358 of the RSUs granted on March 6, 2026 will vest on each of March 6, 2027, March 6, 2028, and March 6, 2029.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apexigen, Inc.
Report date August 23, 2023 · Filed August 25, 2023
Section 16 reporting ended · disclosed 2023-08-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.94 · Expires 2029-11-08 | Direct | 0 |
Reported balance
After 2023-08-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-23 · Disposition to issuer · Disposed 34,084 · Balance 0 F1: The shares subject to the option vest in 48 equal monthly installments beginning on September 16, 2019. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $40.24 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2032-09-29 | Direct | 0 |
Reported balance
After 2023-08-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-23 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in 48 equal monthly installments beginning on September 16, 2019. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $40.24 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
F2: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2024 Filed Mar 5, 2024 20:01 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionCommon Stock | 4,898 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026620 · ownership.xml · nonDerivative · entry 3 Smith Scott Andrew · CIK 0001614975 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Fractional shares have been rounded up in connection with the settlement described in footnote 6 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 20:01 UTC | Viatris Inc VTRS · Entity 3277 | Tax withholdingCommon Stock | 53,449 | $12.59 | $672,922.91 |
DisclosureSEC source: 0000950170-24-026620 · ownership.xml · nonDerivative · entry 2 Smith Scott Andrew · CIK 0001614975 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,380 F1 · shares: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on April 1, 2023. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 20:01 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionCommon Stock | 135,829 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026620 · ownership.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 16:22 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 2,181 | $2.70 | $5,888.70 |
DisclosureSEC source: 0001209191-24-004161 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294,636 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 20:32 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 2,181 | $1.92 | $4,187.52 |
DisclosureSEC source: 0001209191-24-002594 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,817 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 20:17 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $2.46 | $4,405.86 |
DisclosureSEC source: 0001209191-24-000598 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 298,998 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 16:46 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $1.77 | $3,170.07 |
DisclosureSEC source: 0001209191-23-057086 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,789 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| October 31, 2023 Filed Nov 1, 2023 21:17 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $1.47 | $2,632.77 |
DisclosureSEC source: 0001209191-23-054062 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 302,580 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| September 30, 2023 Filed Oct 2, 2023 18:03 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $1.70 | $3,044.70 |
DisclosureSEC source: 0001209191-23-051180 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 304,371 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| August 31, 2023 Filed Sep 1, 2023 20:03 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $2.51 | $4,495.41 |
DisclosureSEC source: 0001209191-23-048033 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 306,162 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 19:37 UTC | Apexigen, Inc. APGN · Entity 110214 | Disposition to issuerStock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $2.65 | Not disclosed |
DisclosureSEC source: 0001209191-23-047452 · doc4.xml · derivative · entry 2 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2032-09-29 F2 · price: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. F2 · derivative.exercise_date: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 19:37 UTC | Apexigen, Inc. APGN · Entity 110214 | Disposition to issuerStock Option (right to buy) · Derivative | 34,084 | Not disclosed Strike: $6.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-047452 · doc4.xml · derivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,084 shares Expires 2029-11-08 F1 · price: The shares subject to the option vest in 48 equal monthly installments beginning on September 16, 2019. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $40.24 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on September 16, 2019. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $40.24 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 17:41 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $2.99 | $5,355.09 |
DisclosureSEC source: 0001209191-23-044048 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 307,953 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 17:43 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $3.00 | $5,373.00 |
DisclosureSEC source: 0001209191-23-040666 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 309,744 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 18:43 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantStock Option (Right to Buy) · Derivative | 5,895 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001209191-23-037549 · doc4.xml · derivative · entry 2 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,895 Underlying: Common Stock · 5,895 shares Expires 2033-06-14 F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 18:43 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001209191-23-037549 · doc4.xml · derivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest and become exercisable on the earlier of (a) June 14, 2024 or (b) the day before the next annual meeting of stockholders, subject to the reporting person continuing to provide services through the vesting date. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 20:24 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $3.15 | $5,641.65 |
DisclosureSEC source: 0001209191-23-033470 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 311,535 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| April 30, 2023 Filed May 2, 2023 18:01 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $3.37 | $6,035.67 |
DisclosureSEC source: 0001209191-23-026658 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,326 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 18:00 UTC | Viatris Inc VTRS · Entity 3277 | GrantRestricted Stock Units · Derivative | 407,485 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-011813 · ownership.xml · derivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 407,485 Underlying: Common Stock · 407,485 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. 135,829 of the RSUs granted on April 1, 2023 will vest on March 3, 2024 and 135,828 will vest on each of March 3, 2025 and March 3, 2026. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. 135,829 of the RSUs granted on April 1, 2023 will vest on March 3, 2024 and 135,828 will vest on each of March 3, 2025 and March 3, 2026. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 20:01 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $2.68 | $4,799.88 |
DisclosureSEC source: 0001209191-23-022427 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · Former President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 315,117 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 18:33 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $2.98 | $5,337.18 |
DisclosureSEC source: 0001209191-23-014294 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · Former President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,908 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| February 10, 2023 Filed Mar 1, 2023 18:33 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantEmployee Stock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001209191-23-014294 · doc4.xml · derivative · entry 2 Smith Scott Andrew · CIK 0001614975 · Director · Former President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2033-02-10 F2 · derivative.exercise_date: The option vests over a period of four years, with 25% of the shares underlying the option vesting on the first anniversary of the date of grant, and the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service to the company through the applicable vesting dates. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 19:09 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 2,181 | $3.79 | $8,265.99 |
DisclosureSEC source: 0001209191-23-006433 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,699 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 17:07 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $8.25 | $14,775.75 |
DisclosureSEC source: 0001209191-23-000318 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,880 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 20:58 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $11.01 | $19,718.91 |
DisclosureSEC source: 0001209191-22-059264 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,671 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| October 31, 2022 Filed Nov 1, 2022 19:54 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $6.89 | $12,339.99 |
DisclosureSEC source: 0001209191-22-055166 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,462 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 19:53 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $7.70 | $13,790.70 |
DisclosureSEC source: 0001209191-22-052558 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,253 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 18:34 UTC | Apexigen, Inc. APGN · Entity 110214 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001209191-22-051953 · doc4.xml · derivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-09-29 F1 · derivative.exercise_date: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Read SEC document |
| August 31, 2022 Filed Sep 1, 2022 18:47 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $8.71 | $15,599.61 |
DisclosureSEC source: 0001209191-22-048363 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,044 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| July 31, 2022 Filed Aug 1, 2022 18:24 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $3.40 | $6,089.40 |
DisclosureSEC source: 0001209191-22-043741 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,835 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 17:23 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $2.85 | $5,104.35 |
DisclosureSEC source: 0001209191-22-040322 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,626 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| May 31, 2022 Filed Jun 3, 2022 18:04 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $2.41 | $4,316.31 |
DisclosureSEC source: 0001209191-22-034299 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,417 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| April 30, 2022 Filed May 6, 2022 16:58 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $3.48 | $6,232.68 |
DisclosureSEC source: 0001209191-22-027629 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,208 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:13 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $5.00 | $8,955.00 |
DisclosureSEC source: 0001209191-22-022743 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,999 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| February 28, 2022 Filed Mar 4, 2022 17:03 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 1,791 | $6.48 | $11,605.68 |
DisclosureSEC source: 0001209191-22-016367 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,790 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:21 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001209191-22-012946 · doc4.xml · derivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-02-22 F1 · derivative.exercise_date: The option vests over a period of four years, with 25% of the shares underlying the option vesting on February 22, 2023, the first anniversary of the date of grant, and the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting dates. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 17:43 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 2,181 | $9.56 | $20,850.36 |
DisclosureSEC source: 0001209191-22-006500 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,581 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| December 31, 2021 Filed Jan 5, 2022 20:33 UTC | BioAtla, Inc. BCAB · Entity 879 | Tax withholdingCommon Stock | 2,894 | $19.63 | $56,809.22 |
DisclosureSEC source: 0001209191-22-002040 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,762 F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units. Read SEC document |
| December 02, 2021 Filed Dec 7, 2021 17:41 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 59 | $22.47 | $1,325.79 |
DisclosureSEC source: 0001209191-21-068385 · doc4.xml · nonDerivative · entry 8 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,656 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F9 · price: The range of prices for the shares of Common Stock is from $22.40 to $22.51. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| December 02, 2021 Filed Dec 7, 2021 17:41 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 2,925 | $21.74 | $63,592.43 |
DisclosureSEC source: 0001209191-21-068385 · doc4.xml · nonDerivative · entry 7 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,715 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F8 · price: The range of prices for the shares of Common Stock is from $21.40 to $22.37. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| December 01, 2021 Filed Dec 7, 2021 17:41 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 76 | $24.22 | $1,841.02 |
DisclosureSEC source: 0001209191-21-068385 · doc4.xml · nonDerivative · entry 6 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,640 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F7 · price: The range of prices for the shares of Common Stock is from $23.80 to $24.68. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| December 01, 2021 Filed Dec 7, 2021 17:41 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 350 | $23.27 | $8,143.10 |
DisclosureSEC source: 0001209191-21-068385 · doc4.xml · nonDerivative · entry 5 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,716 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F6 · price: The range of prices for the shares of Common Stock is from $22.79 to $23.77. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| December 01, 2021 Filed Dec 7, 2021 17:41 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 202 | $22.19 | $4,481.57 |
DisclosureSEC source: 0001209191-21-068385 · doc4.xml · nonDerivative · entry 4 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,066 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F5 · price: The range of prices for the shares of Common Stock is from $21.79 to $22.73. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| November 30, 2021 Filed Dec 7, 2021 17:41 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 74 | $25.38 | $1,878.05 |
DisclosureSEC source: 0001209191-21-068385 · doc4.xml · nonDerivative · entry 3 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,268 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F4 · price: The range of prices for the shares of Common Stock is from $25.30 to $25.38. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| November 30, 2021 Filed Dec 7, 2021 17:41 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 210 | $24.68 | $5,181.96 |
DisclosureSEC source: 0001209191-21-068385 · doc4.xml · nonDerivative · entry 2 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,342 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F3 · price: The range of prices for the shares of Common Stock is from $24.33 to $25.25. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| November 30, 2021 Filed Dec 7, 2021 17:41 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 194 | $24.00 | $4,655.42 |
DisclosureSEC source: 0001209191-21-068385 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,552 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F2 · price: The range of prices for the shares of Common Stock is from $23.33 to $24.32. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| November 29, 2021 Filed Dec 6, 2021 20:42 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 399 | $23.89 | $9,532.11 |
DisclosureSEC source: 0001209191-21-068213 · doc4.xml · nonDerivative · entry 1 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,746 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F2 · price: The range of prices for the shares of Common Stock is from $23.75 to $24.11. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| November 24, 2021 Filed Nov 30, 2021 20:06 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 133 | $25.77 | $3,427.54 |
DisclosureSEC source: 0001209191-21-067219 · doc4.xml · nonDerivative · entry 6 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,145 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F7 · price: The range of prices for the shares of Common Stock is from $25.57 to $26.14. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| November 24, 2021 Filed Nov 30, 2021 20:06 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 160 | $25.00 | $3,999.84 |
DisclosureSEC source: 0001209191-21-067219 · doc4.xml · nonDerivative · entry 5 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,278 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F6 · price: The range of prices for the shares of Common Stock is from $24.48 to $25.42. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| November 24, 2021 Filed Nov 30, 2021 20:06 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 173 | $24.05 | $4,161.17 |
DisclosureSEC source: 0001209191-21-067219 · doc4.xml · nonDerivative · entry 4 Smith Scott Andrew · CIK 0001614975 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,438 F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. F5 · price: The range of prices for the shares of Common Stock is from $23.48 to $24.32. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.